Handelsbanken Fonder AB Grows Stock Holdings in DexCom, Inc. $DXCM

Handelsbanken Fonder AB lifted its position in DexCom, Inc. (NASDAQ:DXCM) by 13.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 551,098 shares of the medical device company’s stock after purchasing an additional 66,713 shares during the quarter. Handelsbanken Fonder AB owned 0.14% of DexCom worth $37,083,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Marshall Wace LLP grew its holdings in DexCom by 260.7% in the 2nd quarter. Marshall Wace LLP now owns 3,822,085 shares of the medical device company’s stock worth $333,630,000 after acquiring an additional 2,762,504 shares during the last quarter. E. Ohman J or Asset Management AB grew its stake in shares of DexCom by 400.2% in the third quarter. E. Ohman J or Asset Management AB now owns 77,492 shares of the medical device company’s stock worth $5,214,000 after purchasing an additional 62,000 shares during the last quarter. Zevenbergen Capital Investments LLC increased its holdings in DexCom by 10.0% during the 3rd quarter. Zevenbergen Capital Investments LLC now owns 685,433 shares of the medical device company’s stock valued at $46,123,000 after purchasing an additional 62,098 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in DexCom by 11.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 212,045 shares of the medical device company’s stock valued at $14,269,000 after purchasing an additional 21,352 shares during the last quarter. Finally, Freestone Capital Holdings LLC lifted its holdings in DexCom by 32.1% in the 2nd quarter. Freestone Capital Holdings LLC now owns 29,823 shares of the medical device company’s stock worth $2,603,000 after buying an additional 7,242 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on DXCM shares. Barclays restated an “underweight” rating and set a $72.00 target price (up from $71.00) on shares of DexCom in a report on Friday, February 13th. Royal Bank Of Canada cut their target price on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating on the stock in a research note on Friday, October 31st. Wells Fargo & Company decreased their price target on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a research note on Friday, February 13th. BTIG Research reiterated a “buy” rating and set a $85.00 target price on shares of DexCom in a report on Wednesday. Finally, Citigroup restated a “buy” rating and issued a $77.00 target price (up from $75.00) on shares of DexCom in a research note on Thursday, December 11th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $85.18.

DexCom Stock Performance

Shares of DXCM opened at $73.43 on Friday. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45. The stock has a market cap of $28.26 billion, a P/E ratio of 34.97, a P/E/G ratio of 1.45 and a beta of 1.49. The business’s 50 day moving average price is $70.24 and its 200-day moving average price is $69.23. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.03. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The company had revenue of $1.26 billion during the quarter, compared to analyst estimates of $1.25 billion. During the same quarter last year, the company earned $0.45 EPS. The firm’s revenue for the quarter was up 13.1% on a year-over-year basis. Equities research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.